Neurocrine Biosciences (NBIX) started a Phase 1 first-in-human study of NBIP-’1968 to assess safety and tolerability for obesity treatment. As an early-stage clinical milestone with limited disclosed efficacy data, the news is modestly positive and may support sentiment around the obesity pipeline.
Neurocrine Biosciences (NBIX) started a Phase 1 first-in-human study of NBIP-’1968 to assess safety and tolerability for obesity treatment. As an early-stage clinical milestone with limited disclosed efficacy data, the news is modestly positive and may support sentiment around the obesity pipeline.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
mildly positive
Sentiment Score
0.10
Ticker Sentiment
